Understand how SHBG affects total and free testosterone, why testing methods matter, and which questions to bring to a clinician.
SHBG, short for sex hormone-binding globulin, is a protein in the blood that binds testosterone. Total testosterone measures circulating testosterone without showing how much is free. Free testosterone refers to testosterone that is not bound to proteins.
The amount of SHBG present can change the relationship between those measurements. Higher SHBG can make total testosterone look relatively higher than free testosterone. Lower SHBG can make total testosterone look relatively lower than free testosterone.
The European Association of Urology's male hypogonadism guideline recommends considering free testosterone when conditions that alter SHBG may affect interpretation. Understanding the difference between the total and free measurements helps explain why a clinician may request more than one hormone result.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret hormone results alongside symptoms and medical history. Decisions about further testing or treatment require an individual clinical assessment.
SHBG, total testosterone and free testosterone are different measurements. A threshold used for one should not be applied to another. Their biological relationship matters more than treating each result as an isolated pass or fail.
The EAU identifies 12 nmol/L as a reliable total-testosterone threshold within its guidance on late-onset hypogonadism. That number is not an SHBG reference range or a free-testosterone cutoff.
The guideline places the threshold within a clinical assessment. It bases diagnosis on compatible symptoms or signs together with low morning total testosterone on at least two occasions. Testing should use a reliable assay under fasting conditions.
The EAU also recommends repeating a total-testosterone result below that threshold before testosterone therapy. A single result is therefore not the entire assessment. The biological question is whether testosterone is consistently low in a man whose clinical picture supports that finding.
For SHBG, the role is different. A high or low result helps explain how a binding protein may be affecting the relationship between total and free testosterone. It does not supply a separate diagnostic threshold for testosterone deficiency.
A relatively higher total-testosterone result does not necessarily mean that free testosterone is also relatively high. Increased SHBG may contribute to that pattern. The next question is whether a free-testosterone assessment would clarify the result.
The reverse pattern also matters. When SHBG is lower, total testosterone can look relatively lower than free testosterone. A clinician may therefore need more information before deciding what the total result represents.
These relationships do not establish the free-testosterone level in an individual man. They explain why the EAU recommends assessing free testosterone in relevant circumstances instead of inferring it from total testosterone alone. This is particularly useful when different hormone results appear difficult to reconcile.
The EAU identifies equilibrium dialysis as the most accurate method for measuring free testosterone. It also recognizes calculation from total testosterone, SHBG and albumin as an alternative.
Albumin therefore matters when a calculated result is being interpreted. Total testosterone and SHBG are not the only inputs. Asking which results were used helps clarify how the free-testosterone value was obtained.
A calculated value depends on its inputs and the calculation method. The EAU supports calculation as an alternative to equilibrium dialysis without treating every calculation or assay as interchangeable. The practical question is not simply whether a report includes free testosterone but how that result was produced.
The guideline specifically cautions against direct free-testosterone immunoassays because they do not accurately estimate free testosterone. That warning should not be extended to every testosterone test. The EAU says standardized automated immunoassays for total testosterone correlate well with LC-MS/MS.
Sampling conditions and laboratory methods can affect testosterone results. The EAU recommends morning fasting testing and repeat measurement when an initial result is abnormally low. It also emphasizes collaboration between clinicians and laboratories to support accurate and comparable measurements.
The guideline describes LC-MS/MS as the most accurate method for sex-steroid evaluation. However, the name of a testing method is only part of the discussion. The clinician also needs to know which hormone measure was tested and whether the sampling conditions were appropriate.
The EAU cites a survey across 27 European countries that reported variation in laboratory practice. Reported differences included immunoassay use and limited adoption of LC-MS/MS for total testosterone. The survey also reported inconsistent procedures before analysis.
The guideline notes that the survey's methodology has been criticized. Its findings should therefore be read as a report of variation rather than a description of every laboratory. For a patient, the useful response is to ask whether results being compared were obtained under comparable conditions.
An SHBG result is not a direct measure of symptoms. In adult men, a high or low SHBG value does not establish a distinct symptom pattern or confirm testosterone deficiency. The EAU instead evaluates symptoms within the broader clinical and biochemical picture.
This matters when the laboratory report and a man's experience seem inconsistent. Symptoms that appear compatible with low testosterone are a reason for clinical assessment. They are not a way to calculate free testosterone or decide whether SHBG must be high or low.
The EAU notes that symptoms associated with hypogonadism are not specific to that condition. Their meaning depends on the wider assessment. A binding-protein result cannot resolve that question by itself.
There are therefore separate questions to address: what symptoms or signs are present and whether hormone testing supports a relevant explanation. SHBG may help interpret the testing side of that discussion. It does not replace the clinical side.
A useful appointment discussion describes the symptoms directly rather than starting with a proposed SHBG diagnosis. The clinician can then consider whether total testosterone is sufficient or whether SHBG and free testosterone would add relevant information.
The EAU lists several health conditions and exposures associated with altered SHBG. These are associations to consider during interpretation, not rules that predict every man's result. They also help explain why medication and health history belong beside the laboratory report.
The guideline lists the following factors as associated with increased SHBG:
The clinical question is whether any relevant factor helps explain the measured result. For example, a thyroid condition and thyroid medication are both details worth including in the history. Their presence does not allow someone to infer a free-testosterone level without assessment.
The EAU lists these factors as associated with decreased SHBG:
Obesity and insulin resistance are especially relevant to understanding why total testosterone and SHBG may need to be considered together. A lower total result should not automatically be interpreted without that binding-protein context. Testostra's explanation of the hormone pattern associated with obesity provides related background.
These lists support a review of health conditions and medicines rather than an attempt to change SHBG as an isolated goal. They do not establish a diet or supplement protocol. Nor do they provide a reason to stop prescribed treatment without speaking to the responsible clinician.
A medication history should include testosterone or anabolic androgenic steroid use because the EAU specifically lists them among factors associated with lower SHBG. That information is relevant to interpreting the result. It should be part of the discussion rather than left separate from the hormone panel.
The most useful next step is to connect the history with the testing question. A clinician can assess whether an SHBG-altering factor makes free testosterone relevant. The same discussion can establish whether repeat testing is needed and which method would best clarify the result.
“Could SHBG be affecting my total testosterone result? Is free testosterone indicated? How was it measured or calculated? Do my health conditions or medicines affect interpretation? Should testing be repeated under morning fasting conditions?”
SHBG adds an interpretation problem that a total testosterone number alone may not resolve, and Testostra explains that relationship through evidence-led hormone education. For men sorting through total testosterone, free testosterone and related biomarkers, its coverage provides clinical context while keeping personal diagnosis and treatment decisions separate from general information.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra